Upgrade to SI Premium - Free Trial

Piper Sandler Reiterates Overweight Rating on Biogen (BIIB) Following Donanemab Delay

March 8, 2024 10:15 AM
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $325.00 price target on Biogen (NASDAQ: BIIB) after news that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles